基本情報
- CAS
78649-41-9- 標準SMILES
CN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I- InChIKey
NJKDOADNQSYQEV-UHFFFAOYSA-N- 分子式
- C17H22I3N3O8
- 平均分子量
- 777.1 g/mol
- 単同位体質量
- 776.8541
概要
Iomeprol is a benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position. It has a role as a xenobiotic, a radioopaque medium and an environmental contaminant. It is an organoiodine compound and a benzenedicarboxamide.
名称と識別子
- 優先名称
- Iomeprol
- IUPAC
- 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-methylamino]-2,4,6-triiodobenzene-1,3-dicarboxamide
- 現地名
- イオメプロール
- 英語名
- IOMEPROL
- 分子式
- C17H22I3N3O8
- 分子量
- 777.09
名称と別名
名称をさらに表示
データベース識別子
- CAS
78649-41-9- PubChem CID
- 3731
- DTXSID
DTXSID1049061- ChEMBL
CHEMBL2107214- ChEBI
CHEBI:31710- UNII
- 17E17JBP8L
- Nikkaji
- J277.762B
物性
構造計算による物性
- XLogP
- -2.3
- 極性表面積
- 180 Ų
- 水素結合供与体数
- 7
- 水素結合受容体数
- 8
- 回転可能結合数
- 10
- 重原子数
- 31
- 形式電荷
- 0
- 複雑度
- 591
実験および物理化学的性質
Human Drugs
Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
物理化学的性質
- 融点
- 263 · 263-265C
- 沸点
- 813.2 · 813.2±65.0 °C(Predicted)
- 比重(密度)
- 420 · d420 1.166; d437 1.161; d420 1.334; d437 1.329; d420 1.446; d437 1.441
- 屈折率
- 20 · nD20 1.3828; nD20 1.4327; nD20 1.4660
- 貯蔵温度
- -20 °C · -20°C Freezer
- 溶解性
- DMSO（微量）、メタノール（微量）
- 酸解離定数(Pka)
- 11.36 · 11.36±0.46(Predicted)
- 外見
- 個体
- 色
- ホワイトからオフホワイト
- InChI
- InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)
- InChIKey
- NJKDOADNQSYQEV-UHFFFAOYSA-N
- SMILES
- C1(C(NCC(O)CO)=O)=C(I)C(N(C(CO)=O)C)=C(I)C(C(NCC(O)CO)=O)=C1I
- CAS データベース
- 78649 · 78649-41-9(CAS DataBase Reference)
- EPAの化学物質情報
- 1 · 1,3-Benzenedicarboxamide, N1,N3-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)methylamino]-2,4,6-triiodo- (78649-41-9)
化学的性質
化学的特性White Solid
安全と法規制
毒性情報
安全データ
- 毒性
- LD50 (400 mgI/ml soln) i.v. in mice, rats (gI/kg): 19.9, 14.5; LD50 (370 mgI/ml soln) i.v. in dogs (gI/kg): >12.5 (Morisetti)
- 安衛法
- 57,57-2
化学と産業
薬理情報
ATC Code
V08AB10
V - Various
QV - Various
Pharmacodynamics
The degree of radiographic enhancement by iomeprol is related to the iodine concentration in the tissue of interest following the administration of iomeprol. However, the exposure-response relationships and time course of pharmacodynamic response of iomeprol have not been fully characterized. At therapeutic concentrations, iomeprol was not shown to cause significant effects on the cardiovascular, central nervous, renal, and complement systems.
Mechanism of Action
Iomeprol is a radiographic iodinated contrast agent that opacifies the vessels and body structures where the contrast agent is present following intravenous or intra-arterial administration, permitting radiographic visualization of the internal structures through attenuation of X-ray photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, the contrast agent does not diffuse into the extravascular space and contrast enhancement is generally due to the presence of contrast within the vascular space. In patients with a disrupted blood-brain barrier, the contrast agent accumulates in the extravascular space in the region of disruption.
FDA Pharmacological Classification
17E17JBP8L
IOMEPROL
Established Pharmacologic Class [EPC] - Radiographic Contrast Agent
Mechanisms of Action [MoA] - X-Ray Contrast Activity
Iomeprol is a Radiographic Contrast Agent. The mechanism of action of iomeprol is as a X-Ray Contrast Activity.
IOMEPROL INJECTION
Absorption, Distribution and Excretion
The maximum concentration (Cmax) and area under the concentration-time curve (AUC) are doseproportional across the dose range of 250 mg iodine/kg to 1,250 mg iodine/kg body weight.
Approximately 90% of the iomeprol dose is excreted unchanged in urine within 24 hours.
The volume of distribution of iomeprol is 0.28 (0.05) L/kg. In rats, iomeprol was shown to cross the placenta and be excreted into breast milk.
The total body clearance is 0.10 (0.01) L/hr/kg.
用途と製造
上流・下流製品情報
上流原料
サプライヤー74 社
補足説明
定義ChEBI: A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position.
関連反応
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…